Same Indication

Pembrolizumab vs Retifanlimab

Pembrolizumab vs Retifanlimab: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Retifanlimab.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days.

Chemical Properties

Type: Pembrolizumab — Antibody; Retifanlimab — Antibody.